Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Adial Pharmaceuticals, Inc. (ADIL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2700-0.0400 (-3.05%)
At close: 04:00PM EDT
1.2400 -0.03 (-2.36%)
After hours: 06:32PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH

    CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, has entered into a research collaboration with the Medical College of Wisconsin, a leading medical school, and Dr. John Auchampach, PhD, Professor and Vice Chair of the Department of Pharmacol

  • GlobeNewswire

    Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

    Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter Ended first quarter with cash and cash equivalents of $12.7 million CHARLOTTESVILLE, Va., May 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorder

  • GlobeNewswire

    Maravai LifeSciences Reports First Quarter 2022 Financial Results

    Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS GuidanceSAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2022, together with other business updates. Highlights include: Record quarterly revenue of $244.3 million, an increase of 65% over the prior year;Nucl

Advertisement
Advertisement